  - $172.29
2.14 (1.26%) - 01/07/19
- HSBC
01/07/19
UPGRADETarget $206
HSBC
Buy HSBC upgrades Constellation Brands to Buy on valuation despite risks HSBC analyst Carlos Laboy upgraded Constellation Brands to Buy from Hold with an unchanged price target of $206. The company is facing increasing risks from water permit uncertainty, a possible vote to shut down the Mexicali brewery, and new national water laws, Laboy tells investors in a research note. The analyst says that despite these risks, he upgrades Constellation to Buy on valuation. His "base case" implies 28% share upside. - 01/07/19
- JEFF
Coca-Cola European Partners upgraded to Buy from Hold at Jefferies Jefferies analyst Kevin Grundy upgraded Coca-Cola European Partners (CCEP) to Buy with an increased price target of EUR 49. The analyst sees inflecting trends, capital deployment optionality and upside to consensus estimates for the company. His top pick in Consumer Products for 2019 is Constellation Brands (STZ). - 01/07/19
- HSBC
Constellation Brands upgraded to Buy from Hold at HSBC - 01/07/19
- SUSQ
01/07/19
UPGRADESUSQ
Neutral Constellation Brands upgraded to Neutral from Negative at Susquehanna STZ.B Constellation Brands; also tag STZ - $172.00
11.78 (7.35%) - 10/18/18
- JEFF
10/18/18
NO CHANGETarget $289
JEFF
Buy Constellation CEO change does not alter bullish view, says Jefferies Jefferies analyst Kevin Grundy says the CEO change at Constellation Brands does not impact his bullish thesis. He keeps a Buy rating on the shares with a $289 price target. While likely a bit earlier than the market anticipated, Bill Newlands appeared to be the clear successor to Rob Sands when he was named President earlier this year, Grundy tells investors in a research note. The analyst says Constellation remains his top large cap growth idea. - 12/10/18
- COWN
12/10/18
NO CHANGETarget $260
COWN
Outperform Constellation Brands a 'shooting star flying under the radar,' says Cowen Cowen analyst Vivien Azer told investors in a research note that Constellation Brands (STZ) remains her overall Top Pick across all of the companies under her coverage going into 2019, contending that best in class revenue growth within U.S. beer, coupled with strong profitability has afforded Constellation the opportunity to leverage this strong operating performance and position it to win over the long term with its notable $4B investment in market leading Canopy Growth (CGC). Azer maintains an Outperform rating and $260 price target on Constellation shares. - 12/18/18
- HOWW
Constellation Brands project facing referendum in Mexico, says Scotia Scotia analyst Eduardo Suarez tells investors in a research note that Constellation Brands' $1.5B project to build a Corona beer plant in Mexico is facing a referendum to see if the project will be canceled after Carlos Urzua, Mexico's Finance Minister, delivered the country's 2019 budget plan, which includes assumptions of 2% growth and 3.4% inflation. Suarez, who calls the development "concerning," says the referendum was requested by a social movement, and is said to face backing from the local electoral institute. If private projects now face referendums, including after construction starts, the analyst says the appetite to invest in the country could suffer materially. - 01/04/19
- WELS
01/04/19
NO CHANGETarget $260
WELS
Outperform Constellation 'one of the most attractive stocks' in Staples, says Wells Fargo Wells Fargo analyst Bonnie Herzog reiterated an Outperform rating and $260 price target on Constellation Brands (STZ), telling investors in a research note that she believes Constellation is one of the most attractive stocks in Staples, given scarcity of growth across the group and the pullback, which she says is "unjustified." While she expects Constellation to lower FY19 EPS guidance to reflect 25c-30c of interest expense from the increased stake in Canopy Growth (CGC), Herzog believes Q3 results may surprise to the upside based on strong performance in Nielsen scanner data through December and potential beer margin upside from lower marketing investments. She sees Q3 results as a potential positive catalyst and encourages long-term investors to accumulate positions in the stock. - $29.63
0.73 (2.53%) - 01/03/19
- BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH). - 01/09/19
- PIPR
01/09/19
INITIATIONTarget $40
PIPR
Overweight Canopy Growth initiated with an Overweight at Piper Jaffray Piper Jaffray analyst Michael Lavery started Canopy Growth with an Overweight rating and $40 price target. The analyst expects "strong" sales growth from the company, driven by "strong sustainable category momentum." Canopy's capacity advantages, beverage partnership, and balance sheet position it well over the near-term, Lavery tells investors in a research note. He also believes the company's clinical trials and intellectual property should add competitive advantages longer term. - 01/09/19
- PIPR
01/09/19
INITIATIONPIPR
Overweight Piper Jaffray rolls out bullish research coverage on Canopy Growth, Tilray Piper Jaffray analyst Michael Lavery initiated coverage of Canopy Growth (CGC) and Tilray (TLRY) with Overweight ratings and price targets of $40 and $90, respectively. The analyst believes the global Cannabis market has the potential to reach $250B-$500B over the long term and $15B-$50B in the near term. The industry's long-term growth opportunities are significant, both from transitioning illicit trade to legal sales and from transitioning sales in health and wellness categories to cannabidiol-infused products, Lavery tells investors in a research note. The analyst expects recreational use to source from illicit trade and alcohol, medical use to source from other medical treatments, and non-psychoactive CBD-infused cannabis products to source users from food, beverage, and personal care categories. Over 25 countries have legal marijuana use today, he points out. Lavery believes federal legalization in the U.S. could potentially come in the next five years. Further, the analyst expects capital flow into the sector will likely continue. |